Trial Profile
I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Mar 2024
Price :
$35
*
At a glance
- Drugs ARX 788 (Primary) ; Cemiplimab (Primary) ; Dostarlimab (Primary) ; Durvalumab (Primary) ; Encequidar+paclitaxel-Athenex (Primary) ; Endoxifen (Primary) ; Evorpacept (Primary) ; Fianlimab (Primary) ; Ganetespib (Primary) ; Ganitumab (Primary) ; Ladiratuzumab-Vedotin (Primary) ; Lasofoxifene (Primary) ; Letrozole (Primary) ; MK 2206 (Primary) ; Nelitolimod (Primary) ; Neratinib (Primary) ; Olaparib (Primary) ; Patritumab (Primary) ; Pembrolizumab (Primary) ; Pertuzumab (Primary) ; Talazoparib (Primary) ; Trastuzumab (Primary) ; Trastuzumab-duocarmazine (Primary) ; Trebananib (Primary) ; Trilaciclib (Primary) ; Tucatinib (Primary) ; Veliparib (Primary) ; Vepdegestrant (Primary) ; Carboplatin; Conatumumab; Cyclophosphamide; Doxorubicin; Figitumumab; Metformin; Paclitaxel; Trastuzumab emtansine
- Indications Advanced breast cancer; Ductal carcinoma; Early breast cancer; HER2 negative breast cancer; HER2 positive breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Biomarker; Registrational; Therapeutic Use
- Acronyms I-SPY; I-SPY 2.2 TRIAL; I-SPY-2; I-SPY2; SURMOUNT
- 21 Mar 2024 According to Agendia media release, the company announced new data from the I-SPY 2 trial showcasing its ImPrint signature for patients with triple negative (TN) breast cancer, shared by I-SPY 2 researchers in an oral presentation at the 14th European Breast Cancer Conference in Milan, Italy.
- 18 Dec 2023 Results (n=134) assessing Efficacy and biomarker discovery of Neoadjuvant trebananib plus paclitaxel-based chemotherapy for stage II/III breast cancer published in the Clinical Cancer Research
- 24 Oct 2023 Results assessing reduction of anthracycline use with a combined imaging and pathology prediction models using retrospective I-SPY data and prospectively tested in I-SPY2 presented at the 48th European Society for Medical Oncology Congress